Welcome to our dedicated page for Tiziana Life Sciences Com news (Ticker: TLSA), a resource for investors and traders seeking the latest updates and insights on Tiziana Life Sciences Com stock.
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) is a clinical-stage biopharmaceutical company whose news flow centers on the development of intranasal foralumab, a fully human anti-CD3 monoclonal antibody, and related immunomodulation programs. Company announcements highlight progress in neuroinflammatory and neurodegenerative indications, including non-active secondary progressive multiple sclerosis, early Alzheimer’s disease, and amyotrophic lateral sclerosis (ALS).
News about Tiziana often covers key clinical milestones. Recent releases describe dosing of patients in a Phase 2 randomized, placebo-controlled trial of intranasal foralumab in early Alzheimer’s disease, including evaluation as monotherapy and in combination with FDA-approved anti-amyloid therapies lecanemab and donanemab. Other updates report on the Expanded Access Program in non-active secondary progressive multiple sclerosis and the acceptance of the company’s ALS Phase 2 trial into the ALS MyMatch Program at the Sean M. Healey & AMG Center for ALS.
Investors following TLSA news can also expect regulatory and safety updates, such as the submission of Development Safety Update Reports to the U.S. Food and Drug Administration, which summarize cumulative exposure and safety findings for intranasal foralumab. Corporate and capital markets news includes insider share purchases by senior leadership, decisions regarding proposed public offerings, and participation in industry conferences like BIO-Europe, the Jefferies London Healthcare Conference, and neuroscience-focused forums.
This news page aggregates these company-issued press releases and related coverage, giving readers a centralized view of Tiziana’s clinical progress, regulatory interactions, strategic initiatives such as the planned spinout of IL-6 asset TZLS-501, and visibility events like ringing the Nasdaq Closing Bell. Users interested in TLSA can review this feed to monitor how Tiziana’s immunotherapy and drug delivery programs evolve over time.
Tiziana Life Sciences (Nasdaq: TLSA) reported biomarker results showing intranasal foralumab reduced PET-measured microglial activation and shifted CSF proteomics toward decreased inflammation and increased neuroprotection in na-SPMS patients with PIRA.
Findings from 10 patients (14 paired evaluations) showed significant PET m-GALP z-score reductions (p<0.05 at 3 months+), strong correlations between PET and CSF proteins (r up to 0.896 and -0.931, p<0.05), clinical stabilization/improvement, and no serious treatment-related adverse events. Phase 2a top-line data expected H1 2026.
Tiziana Life Sciences (Nasdaq: TLSA) announced peer-reviewed publication of an open-label study of intranasal foralumab in non-active secondary progressive multiple sclerosis (na-SPMS) in Neurology Neuroimmunology & Neuroinflammation on Jan 20, 2026. The 10-patient study reported no serious treatment-related adverse events, stabilization of EDSS in all patients with improvement in 3 of 4 treated 12 months, MFIS fatigue improvement in 6 of 10, no new T2 MRI lesions, reduced microglial activation by TSPO-PET (p<0.05), and single-cell RNA-seq showing increased Tregs and TGFβ. A randomized double-blind Phase 2 in na-SPMS is ongoing with top-line data expected in 1H 2026.
Tiziana Life Sciences (Nasdaq: TLSA) closed an oversubscribed registered direct offering of 7,040,000 ordinary shares at $1.25 per share, raising gross proceeds of approximately $8.8 million. Each share issued includes a warrant exercisable at $1.50 through July 16, 2026, which could yield up to ~$10.56 million in additional gross proceeds if fully exercised.
The offering was conducted without an underwriter and was subscribed by senior management and existing shareholders, including CEO Ivor Elrifi who bought 2,400,000 shares and increased his total to 2,757,848 shares, and Executive Chairman Gabriele Cerrone who bought 1,600,000 shares raising his total to 44,974,830 shares. Proceeds are intended to complete Phase 2 na-SPMS and MSA trials and deliver topline data readouts.
Tiziana Life Sciences (Nasdaq: TLSA) priced a registered direct offering of 6,400,000 ordinary shares at $1.25 per share, expected to raise approximately $8.0 million in gross proceeds before expenses. Each share purchased includes a warrant to buy one ordinary share at $1.50 exercisable through July 16, 2026, potentially generating up to an additional $9.6 million. The Offering, conducted without an underwriter and expected to close on January 16, 2026, was led by CEO Ivor Elrifi and included a purchase by Executive Chairman Gabriele Cerrone. Proceeds are intended to fund completion of the company’s Phase 2 na-SPMS and MSA clinical trials and topline data readouts.
Tiziana Life Sciences (NASDAQ: TLSA) said CEO Ivor Elrifi will present at the 9th Annual Neuroscience Innovation Forum on Jan 11, 2026 at 2:00 PM PT at the Marines' Memorial Club in San Francisco during J.P. Morgan Healthcare Conference Week. Senior management will attend and be available for one-on-one investor and partner meetings.
The presentation will highlight the company's lead candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody intended to modulate the immune system and reduce microglial activation in neurodegenerative and neuroinflammatory conditions, including non-active secondary progressive multiple sclerosis.
Tiziana (NASDAQ: TLSA) submitted its seventh annual Development Safety Update Report to the FDA covering Sept 21, 2024–Sept 2, 2025, reporting a cumulative 37.4 patient-years of intranasal foralumab exposure with no drug-related serious adverse events.
Key exposures: 14 naSPMS patients in Expanded Access (50 µg dose) contributed 30.7 patient-years; the TILS-021 randomized trial plus TILS-022 extension added ~5.2 patient-years; one AD patient added 0.5 patient-years. No new risks or safety actions were identified and nasal delivery showed improved tolerability versus prior IV foralumab reports. The company noted an FDA Dec 23, 2025 complete response letter denying approval of Sanofi’s tolebrutinib for nrSPMS and said its Phase 2 naSPMS readout is expected in 2026.
Tiziana Life Sciences (Nasdaq: TLSA) announced that Executive Chairman and Founder Gabriele Cerrone purchased 97,687 common shares on Dec. 19, 2025.
After the purchase his total holding is 43,374,830 common shares, representing 36.08% of issued share capital.
Tiziana Life Sciences (Nasdaq: TLSA) announced that Executive Chairman and Founder Gabriele Cerrone will ring the Nasdaq Closing Bell in Times Square on December 17, 2025 from 3:45 PM to 4:15 PM ET. The ceremony celebrates the company's progress advancing intranasal foralumab, a fully human anti-CD3 monoclonal antibody delivered nasally to target neurodegenerative and inflammatory diseases including multiple sclerosis, Alzheimer's disease, and ALS.
The company noted recent pipeline progress, including dosing the first patient in its Phase 2 Alzheimer's trial, and provided livestream links for the event.
Tiziana Life Sciences (Nasdaq: TLSA) announced that the first patient was dosed on December 17, 2025 in its randomized, placebo-controlled Phase 2 trial of intranasal foralumab for early Alzheimer’s disease.
The trial will evaluate foralumab as monotherapy and combined with FDA-approved anti-amyloid therapies lecanemab (Leqembi) or donanemab, and is supported by TSPO-PET imaging data showing persistent microglial activation after amyloid reduction. The program tests an immunomodulatory approach targeting residual neuroinflammation with intranasal anti-CD3 foralumab; enrollment will continue and clinical outcomes are pending.
Tiziana Life Sciences (Nasdaq: TLSA) announced on December 15, 2025 that its Chief Executive Officer, Ivor Elrifi, purchased 163,400 shares of Tiziana common stock in the open market.
Following this transaction, the CEO's total purchased shares amount to 357,848. The purchase was executed on the open market and reflects an insider buy by the company's chief executive.